What Is the Abilify Maintena Equivalent Oral Dose?

Abilify Maintena (aripiprazole once-monthly, or AOM) at its standard 400 mg dose produces blood levels roughly equivalent to taking 15 to 20 mg of oral aripiprazole per day. That equivalence is based on pharmacokinetic modeling and observed trough concentrations at steady state, not a simple milligram-to-milligram conversion. The relationship is more nuanced than a single number suggests, though, because the injectable and oral forms deliver aripiprazole to the body on very different timelines, and the way you start the injection matters as much as the maintenance dose.

How Researchers Arrived at the 15 to 20 mg Equivalence

Aripiprazole given as a once-monthly injection does not behave like a pill you take every day. The medication sits as a depot in your muscle tissue and slowly releases into the bloodstream over weeks. Because of that slow release, the peaks and valleys in drug levels are much flatter than what you see with daily oral dosing. A pharmacokinetic study comparing deltoid and gluteal injection sites found that the minimum aripiprazole concentrations achieved by the 400 mg once-monthly injection are comparable to those seen with oral aripiprazole at 15 to 20 mg per day.¹ That range covers the most commonly prescribed oral doses for schizophrenia maintenance.

The lower maintenance dose of Abilify Maintena, 300 mg once monthly, is generally considered equivalent to roughly 10 to 15 mg of oral aripiprazole per day. This dose is typically reserved for situations where a prescriber expects higher-than-usual drug levels, such as when someone is a poor metabolizer of the enzyme CYP2D6 or is taking a strong CYP2D6 or CYP3A4 inhibitor that slows aripiprazole breakdown. In those cases, using the full 400 mg dose could push blood levels uncomfortably high.

One thing that trips people up is assuming the equivalence means the 400 mg injection replaces a 400 mg oral dose. It does not work that way. The 400 mg refers to the total amount of drug deposited into the muscle, which then trickles out over the month. Only a fraction is circulating at any given time, which is why the effective oral equivalent is a much smaller daily number.

Why You Still Need Pills When Starting the Injection

The depot injection takes time to build up in your system. After the first shot, aripiprazole levels from the injection alone are not high enough to be therapeutic for roughly two weeks. To bridge that gap, the standard initiation protocol calls for a 400 mg injection on day one plus 14 consecutive days of oral aripiprazole at 10 mg per day. Simulation modeling confirmed that this two-week overlap was the most reliable way to keep drug levels in the therapeutic window during the transition from pills to the monthly shot.²

If you were previously stable on oral aripiprazole at, say, 20 or 30 mg per day, you still drop to 10 mg for those 14 days. The idea is not to replicate your full prior oral dose during the overlap; it is simply to maintain a therapeutic floor while the depot builds up. After those two weeks, the injection takes over entirely and no further oral supplementation is needed.

For people who were not taking oral aripiprazole at all before starting Abilify Maintena, prescribers typically establish tolerability with oral aripiprazole first, often for about two weeks, before giving the first injection. This confirms the person can handle aripiprazole without troublesome side effects before committing to a month-long depot.

The Two-Injection Start as an Alternative

The 14-day oral overlap works well in outpatient settings where someone can reliably take a pill each morning. In inpatient settings, where the goal is often rapid stabilization and faster discharge, a newer approach has gained traction: the two-injection start. Instead of one injection plus two weeks of pills, the patient receives two 400 mg injections on the same day (one in each arm or one in the arm and one in the gluteal muscle) along with a single 20 mg oral dose. Population pharmacokinetic modeling showed that this two-injection start produces aripiprazole blood levels comparable to the standard single-injection-plus-14-day-oral protocol.³

A retrospective study of female patients with schizophrenia or bipolar disorder compared the two approaches head to head. Patients who received the two-injection start were discharged sooner, with an average hospital stay of about 8 days versus nearly 12 days for those on the standard protocol. Even more striking, one-year rehospitalization rates were roughly half as high in the two-injection group.⁴ That last finding probably reflects the elimination of a 14-day window during which someone could stop taking the oral supplement and lose coverage. With the two-injection start, there is no daily pill to forget or refuse.

How the Injectable Compares to Oral Aripiprazole in Preventing Relapse

Dose equivalence only matters if the injectable actually works as well as the oral form at those equivalent levels. Clinical trials have confirmed that it does. In pivotal studies, Abilify Maintena was found to be noninferior to oral aripiprazole in delaying relapse and reducing relapse rates in people with schizophrenia.⁵ “Noninferior” in this context means it performed at least as well by the pre-set statistical threshold. In other words, switching from oral to injectable aripiprazole does not sacrifice clinical protection when the equivalent dose relationship holds.

This is reassuring, but it also comes with a caveat that applies to all long-acting injectables: if you have a bad reaction, you cannot just stop taking it the way you would stop a pill. The drug will continue releasing from the depot for weeks. Prescribers weigh this tradeoff differently depending on the patient’s history, side-effect profile, and how well they tolerate oral aripiprazole beforehand.

Abilify Maintena Versus Aristada and Why the Doses Look Different

Aripiprazole comes in two distinct long-acting injectable formulations, and confusing them is easy. Abilify Maintena (aripiprazole monohydrate) is dosed at 300 or 400 mg monthly. Aristada (aripiprazole lauroxil) is a different prodrug formulation with its own dosing schedule and its own set of available strengths, including 441, 662, 882, and 1064 mg options given at varying intervals.

Despite both delivering aripiprazole, the two products are not interchangeable milligram for milligram. Pharmacokinetic simulations found that the average steady-state concentrations from Aristada at 882 mg every four weeks were roughly comparable to those from Abilify Maintena at 400 mg, though trough levels with Aristada 882 mg were slightly lower.⁶ The lower Aristada doses, 441 mg and 662 mg every four weeks, produced substantially lower drug levels than Abilify Maintena 400 mg. Clinicians switching a patient between the two formulations need to account for these differences rather than assuming equivalent dose labels translate to equivalent exposure.

Liver and Kidney Problems Do Not Change the Equivalent Dose

One of aripiprazole’s convenient properties is that it does not require dose adjustments for people with impaired liver or kidney function. A dedicated pharmacokinetic study found no meaningful differences in how aripiprazole is processed between people with normal organ function and those with hepatic or renal impairment.⁷ This means the oral-to-injectable equivalence of 400 mg monthly matching roughly 15 to 20 mg daily holds regardless of whether someone has compromised organs. The exceptions that do require dose reductions, as mentioned earlier, involve drug interactions and genetic enzyme differences, not organ function.

The Adherence Advantage and What It Means for Outcomes

The reason the oral-to-injectable dose question comes up so often is that many patients and prescribers are considering the switch specifically because daily pills are hard to take consistently. The data backs up that concern. In a real-world study using U.S. insurance claims, patients with schizophrenia on Abilify Maintena had significantly better medication adherence than those on oral antipsychotics, and the oral group was about 45 percent more likely to discontinue treatment entirely. For patients with bipolar I disorder, the gap was even wider: oral users were roughly 71 percent more likely to stop their medication.⁸

Better adherence translates into real clinical differences. A 10-year mirror-image study, which compared each person’s outcomes before and after starting the long-acting injectable, found striking results: among those who stayed on treatment for five years, hospitalizations dropped by nearly 90 percent and the total days spent in the hospital fell from an average of 103 to just 10.⁹ A European real-world study similarly found that about 82 percent of patients were still on Abilify Maintena at six months, with employment and milder illness severity at baseline predicting better persistence.¹⁰

These numbers do not mean the injectable is pharmacologically superior to the oral form at equivalent doses. Recall that clinical trials showed noninferior efficacy. The injectable’s real-world advantage comes from removing the daily decision point. You cannot accidentally skip a dose you received in a clinic last month.

Cost Considerations

Abilify Maintena is substantially more expensive than generic oral aripiprazole, which has been available since 2015. Whether the injectable is cost-effective depends on how often a given patient would relapse, be hospitalized, or stop treatment on the oral version. Economic modeling for bipolar I disorder estimated that Abilify Maintena resulted in fewer mood episodes and hospitalizations per patient than several comparators, including oral alternatives and other long-acting injectables. It was cost-effective or even cost-saving compared to long-acting injectable risperidone, paliperidone palmitate, and best supportive care.¹¹ For a patient who takes oral aripiprazole reliably every day and rarely relapses, the economic case for the injectable is harder to make. The benefit concentrates among people whose illness course involves frequent hospitalizations or treatment gaps.

What Patients Report About Switching

The dose equivalence question sometimes masks a deeper concern: will the injectable feel the same as the pills? Surveys of patients who have experience with both forms offer some insight. Among those who preferred the long-acting injectable, the most commonly cited reasons were that it was easier, that they felt more in control of their treatment by not having to think about daily dosing, and that they experienced fewer sudden symptoms. Interestingly, among the minority who preferred pills, the most common reason was feeling less embarrassed: receiving an injection in a clinic carries a social visibility that swallowing a pill at home does not.¹²

These preferences matter clinically because a patient who resents their treatment is less likely to show up for the next injection. The 82 percent six-month persistence rate cited earlier is encouraging, but it also means nearly one in five patients stops within half a year. For prescribers weighing the switch, having a candid conversation about how the patient feels about monthly clinic visits, injection-site discomfort, and the loss of day-to-day control over whether to take medication is just as important as getting the dose equivalence right.

When the Standard Equivalence Might Not Apply

The 400 mg injection equals roughly 15 to 20 mg oral rule works for the average adult, but several situations shift the math. People who are CYP2D6 poor metabolizers, meaning they break down aripiprazole more slowly than most, effectively get more drug exposure from the same dose. Strong CYP2D6 inhibitors like fluoxetine or paroxetine, or strong CYP3A4 inhibitors like ketoconazole, have a similar effect by slowing the enzyme systems that clear aripiprazole. In these cases, prescribers typically drop to the 300 mg injection to avoid overshooting the target blood level.

On the flip side, strong CYP3A4 inducers like carbamazepine speed up aripiprazole metabolism and can pull blood levels below the therapeutic range. For oral aripiprazole, the standard response is to increase the dose. With Abilify Maintena, there is no dose above 400 mg, so co-administration with a potent inducer can undermine the injection’s effectiveness. This is one of the few situations where the injectable genuinely cannot replicate what oral dosing could achieve, because oral doses can be pushed to 30 mg per day to compensate.

Body weight and injection site also introduce some variability. The deltoid muscle generally produces slightly higher peak concentrations than the gluteal site for the same dose, probably because of differences in blood flow and fat-to-muscle ratio. For most patients, the difference is not clinically meaningful, but in someone who is borderline on drug levels, it could matter enough that a prescriber might prefer one injection site over the other.